# US 9,375,468 B2 · Prevention of inflammatory disorders in domestic non-human mammals > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,375,468 B2 - Document ID: US9375468B2 - Status: Granted - Kind: B2 - Application number: 14/377,450 - Filed: 2013-02-05 - Published: 2015-03-19 - Granted: 2016-06-28 - Earliest claimed: 2012-02-08 - Assignees: Premune AB - Applicants: Premune AB - Inventors: Ingegerd Adlerberth; Anna Rudin; Agnes Wold - Web page: https://patentgrep.com/patent/US9375468B2 ## CPC - A61K 39/092: {Streptococcus} - A61K 38/164: {from bacteria} - A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance} - A61K 39/085: Staphylococcus - A61P 17/00: Drugs for dermatological disorders - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 37/00: Drugs for immunological or allergic disorders - A61P 37/02: Immunomodulators - A61P 37/04: Immunostimulants - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - A61K 2039/545: {characterised by the dose, timing or administration schedule} - A61K 2039/552: {Veterinary vaccine} - A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention regards use of a bacterial superantigen for administration onto the mucous membrane of a domestic non-human mammal for the prevention of inflammatory disorder, such as allergies, autoimmune and inflammatory diseases. ## Claims ### Claim 1 A method for reducing the incidence of, or for prophylactic treating, an inflammatory disorder in a domestic non-human mammals, wherein the domestic animal is a dog, a cat, or a horse, the method comprising administering a pharmaceutical composition comprising a bacterial superantigen to a mucous membrane of a newborn of said domestic non-human mammals. ### Claim 2 (depends on 1) The method according to claim 1, wherein the pharmaceutical composition comprises at least one strain of the Staphylococcus aureus producing enterotoxin. ### Claim 3 (depends on 1) The method according to claim 1, wherein the pharmaceutical composition comprises at least one of the Staphylococcus aureus enterotoxins A, B, C1, C2, C3, D, E, G or H, enterotoxin-like toxins Q, M or K, or toxic shock syndrome toxin (TSST)-1. ### Claim 4 (depends on 1) The method according to claim 1, wherein the pharmaceutical composition comprises at least one streptococcal strain producing superantigen. ### Claim 5 (depends on 1) The method according to claim 1, wherein the pharmaceutical composition comprises at least one streptococcal superantigen. ### Claim 6 (depends on 5) The method according to claim 5, wherein said streptococcal superantigen is a streptococcal pyrogenic exotoxin, a streptococcal mitogenic exotoxin, or streptococcal superantigen A. ### Claim 7 (depends on 3) The method according to claim 3, wherein the superantigen in the pharmaceutical composition is Staphylococcus aureus enterotoxin C1, C2 or C3. ### Claim 8 (depends on 7) The method according to claim 7, wherein the superantigen in the pharmaceutical composition is Staphylococcus aureus enterotoxin C2. ### Claim 9 (depends on 1) The method according to claim 1, wherein the pharmaceutical composition is administered onto the intestinal mucous membrane of said newborn domestic non-human mammal. ### Claim 10 (depends on 1) The method according to claim 1, wherein the pharmaceutical composition is administered onto the nasal mucous membrane of said newborn domestic non-human mammal, or onto mucous membrane in the oral cavity of said newborn domestic non-human mammal. ### Claim 11 (depends on 1) The method according to any of the claim 1, wherein the pharmaceutical composition is administered to the newborn domestic non-human mammals within 3 months after birth. ### Claim 12 (depends on 1) The method according to claim 1, wherein the pharmaceutical composition is administered multiply. ### Claim 13 (depends on 1) The method according to claim 1, wherein the inflammatory disorder is an allergy. ### Claim 14 (depends on 13) The method according to claim 13, wherein the allergy is food allergy or atopic dermatitis. ### Claim 15 (depends on 1) The method according to claim 1, wherein the inflammatory disorder is an inflammatory disease. ### Claim 16 (depends on 1) The method according to claim 1, wherein the inflammatory disorder is an autoimmune disease. ### Claim 17 (depends on 1) The method according to claim 1, wherein the domestic animal is a dog or a cat. ### Claim 18 (depends on 17) The method according to claim 17, wherein the domestic animal is a dog. ### Claim 19 (depends on 11) The method according to claim 11, wherein the pharmaceutical composition is administered to the newborn domestic non-human mammal within 2 weeks after birth. ### Claim 20 (depends on 19) The method according to claim 19, wherein the pharmaceutical composition is administered to the newborn domestic non-human mammal within 10 days after birth. ### Claim 21 (depends on 20) The method according to claim 20, wherein the pharmaceutical composition is administered to the newborn domestic non-human mammal within 7 days after birth.